Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial.

Autor: Chacon Alberty L; Regenerative Medicine Department, Texas Heart Institute, Houston, TX, United States., Perin EC; Stem Cell Center, Texas Heart Institute, Houston, TX, United States., Willerson JT; Stem Cell Center, Texas Heart Institute, Houston, TX, United States., Gahremanpour A; Hospital Corporation of America-Houston Heart, Houston, TX, United States., Bolli R; School of Medicine, University of Louisville, Louisville, KY, United States., Yang PC; Stanford University School of Medicine, Stanford, CA, United States., Traverse JH; Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital and University of Minnesota School of Medicine, Minneapolis, MN, United States., Lai D; UTHealth School of Public Health, Houston, TX, United States., Pepine CJ; University of Florida College of Medicine, Gainesville, FL, United States., Taylor DA; Regenerative Medicine Department, Texas Heart Institute, Houston, TX, United States.
Jazyk: angličtina
Zdroj: Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2021 Sep 03; Vol. 8, pp. 698088. Date of Electronic Publication: 2021 Sep 03 (Print Publication: 2021).
DOI: 10.3389/fcvm.2021.698088
Abstrakt: Cell therapy trials for heart failure (HF) have shown modest improvement; however, the mechanisms underlying improvement in some patients but not others are not well understood. Although immune cells are important in the course of HF, our understanding of the immune processes in HF is limited. The objective of this study was to evaluate associations between temporal changes in peripheral blood (PB) cell subpopulations and improved outcome in patients with chronic ischemic cardiomyopathy after bone marrow-derived mononuclear cell therapy or placebo in the FOCUS-CCTRN trial. Peripheral blood was collected at days 0, 1, 30, 90, and 180 from consented participants. We used flow cytometry to compare PB populations in patients with the best (cohort 1) or worst functional outcome (cohort 2) in three primary endpoints: left ventricular (LV) ejection fraction, LV end-systolic volume, and maximal oxygen consumption (VO 2 max). A linear mixed model was used to assess changes over time in 32 cell populations. The difference between each time point and baseline was calculated as linear contrast. Compared with cohort 2, patients who improved (cohort 1) had a higher frequency of CD45 + CD19 + B cells at days 0, 1, 90, and 180. CD11B + cells increased over baseline at day 1 in both cohorts and remained higher in cohort 2 until day 30. CD45 + CD133 + progenitor cells decreased over baseline at day 30 in cohort 1. We identified specific cell subpopulations associated with improved cardiac function in patients with chronic LV dysfunction. These findings may improve patient selection and prediction of outcomes in cell therapy trials.
Competing Interests: DT has a financial interest in Miromatrix Medical, Inc. DT have financial interests in Stem Cell Security, LLC. This relationship was monitored in accordance with the conflict of interest policies by the Texas Heart Institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Chacon Alberty, Perin, Willerson, Gahremanpour, Bolli, Yang, Traverse, Lai, Pepine and Taylor.)
Databáze: MEDLINE
Externí odkaz: